CYOU News Alert Changyou.Com Limited (CYOU) 25.85 12/25/2014

New Post Public Reply Private Reply Replies (0) Message Board

Dec 25, 2014 at 5:49 PM

Changyou.Com Limited (CYOU) 25.85 $CYOU

Changyou.com Ltd Up 34.4% Since SmarTrend Uptrend Call (CYOU)
Comtex SmarTrend(R) - Fri Dec 19, 9:38AM CST
SmarTrend identified an Uptrend for Changyou.com Ltd (NASDAQ:CYOU) on October 28th, 2014 at $19.42. In approximately 2 months, Changyou.com Ltd has returned 34.40% as of today's recent price of $26.10.
CYOU: 25.85 (+0.42)

Sohu +3.3%, Changyou +3.9% on JPMorgan upgrade
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 9:31AM CST

CYOU: 25.85 (+0.42), SOHU: 51.80 (-0.22)

Uptrend Call Working As Changyou.com Ltd Stock Rises 16.9% (CYOU)
Comtex SmarTrend(R) - Fri Dec 12, 9:13AM CST
SmarTrend identified an Uptrend for Changyou.com Ltd (NASDAQ:CYOU) on October 28th, 2014 at $19.42. In approximately 2 month, Changyou.com Ltd has returned 16.89% as of today's recent price of $22.70.
CYOU: 25.85 (+0.42)

Changyou.com Ltd Shares Up 16.0% Since SmarTrend's Buy Recommendation (CYOU)
Comtex SmarTrend(R) - Wed Dec 03, 5:02PM CST
SmarTrend identified an Uptrend for Changyou.com Ltd (NASDAQ:CYOU) on October 28th, 2014 at $19.42. In approximately 1 month, Changyou.com Ltd has returned 16.01% as of today's recent price of $22.53.
CYOU: 25.85 (+0.42)

Changyou.com Ltd Has Returned 17.9% Since SmarTrend Recommendation (CYOU)
Comtex SmarTrend(R) - Wed Nov 26, 11:15AM CST
SmarTrend identified an Uptrend for Changyou.com Ltd (NASDAQ:CYOU) on October 28th, 2014 at $19.42. In approximately 4 weeks, Changyou.com Ltd has returned 17.87% as of today's recent price of $22.89.
CYOU: 25.85 (+0.42)

Shares of CYOU Up 16.1% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Wed Nov 19, 10:01AM CST
SmarTrend identified an Uptrend for Changyou.com Ltd (NASDAQ:CYOU) on October 28th, 2014 at $19.42. In approximately 3 weeks, Changyou.com Ltd has returned 16.12% as of today's recent price of $22.55.
CYOU: 25.85 (+0.42)

Update: Changyou.com Q3 2014 Earnings
Andy Batts - at Seeking Alpha - Fri Nov 14, 9:14PM CST

CYOU: 25.85 (+0.42)

NetEase Earnings Climb; Latest "World of Warcraft" Installment on Tap
Dan Caplinger, The Motley Fool - Motley Fool - Thu Nov 13, 12:06PM CST
NetEase's Westward Journey II . Source: Chinagame.178.com Online gaming has fallen out of the spotlight lately in the U.S., as social-media companies have largely turned to other sources of revenue and left gaming to specialist companies with...
ATVI: 20.35 (+0.12), NTES: 101.31 (+0.90), CYOU: 25.85 (+0.42), PWRD: 15.68 (-0.05)

The Zacks Analyst Blog Highlights: Alibaba Group Holding, Mindray Medical International, Changyou.com, NetEase and China Mobile
PR Newswire - Fri Nov 07, 8:30AM CST
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Alibaba Group Holding Ltd. (NYSE:BABA-Free Report), Mindray Medical International Ltd. (NYSE:MR-Free Report), Changyou.com Ltd. (Nasdaq:CYOU-Free Report), NetEase, Inc. (Nasdaq:NTES-Free Report) and China Mobile Ltd. (NYSE:CHL-Free Report).
CYOU: 25.85 (+0.42), MR: 26.87 (+0.30), BABA: 105.95 (+0.43)

China Stock Roundup: Alibaba Misses, Mindray Meets Estimates - Analyst Blog
Swarup Gupta - Zacks Investment Research - Thu Nov 06, 9:41AM CST
Markets experienced another largely positive week, indicating that the economy is responding positively to the government's reform agenda.
WB: 14.75 (-0.03), NTES: 101.31 (+0.90), CHL: 59.15 (-0.02), CYOU: 25.85 (+0.42), MR: 26.87 (+0.30), BABA: 105.95 (+0.43)

Sohu.com Inc. Earnings: China Searches for Growth
Rick Munarriz, The Motley Fool - Motley Fool - Mon Nov 03, 11:52AM CST
Source: Sohu.com. There is still growth to be found through most of Sohu.com . The dot-com pioneer with interests in portals, gaming, video, and search, posted another quarter of double-digit top-line growth, but it's important to break down...
BIDU: 230.98 (-2.18), SOHU: 51.80 (-0.22), CYOU: 25.85 (+0.42)

Changyou.com Limited's (CYOU) CEO Dewen Chen on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Nov 03, 10:10AM CST

CYOU: 25.85 (+0.42)

Sohu, Changyou turn positive
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 9:11AM CST

SOHU: 51.80 (-0.22), CYOU: 25.85 (+0.42)

Changyou Q3 FY2014 Results
China Stock Research - at Seeking Alpha - Mon Nov 03, 9:05AM CST
Changyou.com (NASDAQ: CYOU ) released Q3 FY2014 results which included revenue of 181 million USD (missing management's earlier guidance) and net income of 1.5 million USD. Results for Q3 missed the consensus revenue estimate of about 189 million...
CYOU: 25.85 (+0.42)

Sohu -4.2%, Changyou -12.2%; Changyou's CEO resigns
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 8:15AM CST

SOHU: 51.80 (-0.22), CYOU: 25.85 (+0.42)

Changyou.com Limited (CYOU) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Mon Nov 03, 5:55AM CST

CYOU: 25.85 (+0.42)

Changyou.com beats by $0.13, misses on revenue
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 4:50AM CST

CYOU: 25.85 (+0.42)

Changyou Reports Third Quarter 2014 Unaudited Financial Results and Announces Management Changes
PR Newswire - Mon Nov 03, 2:45AM CST
Changyou.com Limited ("Changyou" or the "Company"

(NASDAQ: CYOU), a leading online game developer and operator in China, today announced its unaudited financial results for the third quarter ended September 30, 2014.
SOHU: 51.80 (-0.22), CYOU: 25.85 (+0.42)

Sohu.com Reports Third Quarter 2014 Unaudited Financial Results and Management Changes at Changyou.com
PR Newswire - Mon Nov 03, 2:45AM CST
Sohu.com Inc. (NASDAQ: SOHU), China's leading online media, search, gaming, community and mobile service group, today reported unaudited financial results for the third quarter ended September 30, 2014.
CYOU: 25.85 (+0.42), SOHU: 51.80 (-0.22)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Championing Change: USTA Mid-Atlantic Gala's Impact

A Night to Remember: USTA Mid-Atlantic's Gala Who would've thought tennis could wield such transformative power? This ain't your average sport gala. Last Saturday, a crowd of over 300 gathered at the Ritz-Carlton Tysons Corner for the USTA Mid-Atlantic Foundation's 2026 Tennis Creates Gala. Hosted by the formidable Malika Andrews, this event wasn't just a fancy...

Viking Ventures: Impacts of VK2735 on Obesity Examined

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

EZaccessMD Data Breach: Class Action Lawsuit Looms

Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...

D-Wave Quantum Hit with Securities Fraud Lawsuit

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Beef 'O' Brady's Expands Into Tuscaloosa Market

A New Player in Town: Beef 'O' Brady's Lands in Tuscaloosa Listen up, sports fans and pub grub lovers of Tuscaloosa! Beef 'O' Brady's just kicked down the doors and expanded its reach, opening a location smack on McFarland Boulevard. The place threw open its doors on October 26 and is set to make waves in the local scene, driven by the dedicated hands of Mitul Patel and...

Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

IDEAYA's IDE101: A New Front in Cancer Battle

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...